Q32 Bio Inc. handed off rights to phase II-stage complement inhibitor ADX-097 in a deal with Akebia Therapeutics Inc. that helps the former extend its cash runway to focus on lead candidate bempikibart in alopecia areata and bolsters the latter’s efforts to build a rare kidney disease pipeline.
A 24‑week pregnant woman fears for her unborn baby, who is developing with a sacrococcygeal teratoma so large and vascularized that it nearly surpasses the size of the fetus itself. Faced with this threat, surgeons operate inside the uterus in an open procedure that partially exposes the baby to remove the tumor and give the baby a chance to survive until birth. According to scientists presenting at the American Society of Gene & Cell Therapy's special meeting on Breakthroughs in Targeted In Vivo Gene Editing, this could be avoided.
Genescience Pharmaceuticals Co. Ltd. has divulged thyroid-stimulating hormone (thyrotropin) receptor (TSHR) antagonists reported to be useful for the treatment of hyperthyroidism, Grave’s disease and thyroid-associated ophthalmopathy (Grave’s ophthalmopathy).
Di’ao Group Chengdu Pharmaceutical Co. Ltd. has identified glucagon-like peptide 1 receptor (GLP-1R) agonists reported to be useful for the treatment of diabetes, dementia, obesity, metabolic syndrome, metabolic dysfunction-associated steatotic liver disease (MASLD), dyslipidemia, stroke and cardiovascular disorders, among others.
The canonical G protein-coupled receptors (GPCRs) cannabinoid CB1 (CB1R) and CB2 (CB2R) receptors are the most studied in the endocannabinoid system. CB1R is widely distributed throughout the CNS, but is also present on peripheral tissues.
Regeneron Pharmaceuticals Inc. and Tessera Therapeutics Inc. have established a global collaboration to develop and commercialize TSRA-196, Tessera’s lead investigational in vivo gene editing program for the treatment of α-1 antitrypsin deficiency (AATD).
Ascletis Pharma Inc. has selected ASC-37 oral tablets as a clinical development candidate for the treatment of obesity. The company expects to submit an IND application to the FDA in the second quarter of next year.
Kedrion SpA’s investigational plasma-derived treatment for congenital aceruloplasminemia has been awarded European orphan drug designation by the EMA. The company is working to advance this treatment toward clinical development in Europe.
In an effort to identify stronger and safer α-glucosidase inhibitors, researchers at the Chinese Academy of Sciences prepared a series of diarylpentane derivatives, the most promising of which, [I], reversibly inhibited α-glucosidase with an IC50 of 18 µM.
CSPC Pharmaceutical Group Ltd. has gained clinical trial clearance from China’s National Medical Products Administration (NMPA) for JMT-206 for weight management in individuals with obesity or overweight and at least one weight-related comorbidity.
RSS
